Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLCs registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medivir receives €2.6 million for hepatitis C collaboration

This article was originally published in Scrip

Executive Summary

Medivir has received a €2.6 million milestone payment from Tibotec after the Belgian Johnson & Johnson subsidiary selected a hepatitis C preclinical development candidate. The Swedish firm has a research, development and licence agreement with Ortho Biotech Products and Tibotec to identify and develop orally active inhibitors of the hepatitis C virus polymerase NS5B (Scrip Online, May 21st, 2008). Tibotec is responsible for the development of the candidate through to marketing and has exclusive worldwide marketing rights except in the Nordic countries, which Medivir has retained. The two firms are developing TMC435 (formerly TMC435350), currently in Phase IIa studies, which inhibits the NS3 protease enzyme.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC007710

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel